Filing Details
- Accession Number:
- 0001209191-21-012326
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-19 16:07:51
- Reporting Period:
- 2021-02-18
- Accepted Time:
- 2021-02-19 16:07:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1434316 | Fate Therapeutics Inc | FATE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586893 | Scott J Wolchko | C/O Fate Therapeutics, Inc.; 3535 General Atomics Court #200 San Diego CA 92121 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-02-18 | 20,000 | $6.62 | 413,793 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-02-18 | 1,401 | $99.08 | 412,392 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 1,848 | $100.48 | 410,544 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 2,602 | $101.42 | 407,942 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 8,602 | $102.26 | 399,340 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-02-18 | 5,547 | $103.16 | 393,793 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-02-18 | 20,000 | $0.00 | 20,000 | $6.62 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,846 | 2024-01-08 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020.
- Represents the weighted average sale price of the shares sold ranging from $98.65 to $99.645 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $99.825 to $100.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $100.83 to $101.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $101.85 to $102.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- Represents the weighted average sale price of the shares sold ranging from $102.86 to $103.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.
- This option is fully vested.
- Not applicable.
Billionaire Hedge Funds
